Zoonotic Disease Treatment Market Report 2026

Zoonotic Disease Treatment Market Overview

• Zoonotic Disease Treatment market size has reached to $42.51 billion in 2025 • Expected to grow to $57.77 billion in 2030 at a compound annual growth rate (CAGR) of 6.2% • Growth Driver: Increased Demand For Animal Proteins Drives Growth In Zoonotic Disease Treatment Market • Market Trend: Investments in Zoonotic Disease Treatment: Major Companies Focus on Advanced Diagnostics and Therapeutic Innovations • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Zoonotic Disease Treatment Market?

Zoonotic disease treatment refers to the medical interventions and therapies aimed at diagnosing, managing, and preventing illnesses caused by pathogens transmitted between animals and humans. This treatment involves a combination of medication, vaccination, hygiene practices, and control measures to reduce transmission and mitigate the impact of these infections on both animal and human populations. The main types of diseases in zoonotic disease treatment are rabies, tuberculosis, malaria, leishmaniasis, Ebola virus disease, and others. Rabies is a viral disease that causes acute inflammation of the brain in humans and other mammals and is typically transmitted through the bite of an infected animal. The drug classes of zoonotic disease treatment are anti-fungal, anti-bacterial, antibiotics, and others and it is caused by various agents such as bacteria, virus, nematode, rodents, ticks, and others. The route of administration includes oral, topical, and others and it is distributed by channels such as hospital pharmacy, retail pharmacy, online pharmacy, and others.

What Is The Zoonotic Disease Treatment Market Growth Forecast?

The zoonotic disease treatment market size is expected to see strong growth in the next few years. It will grow to $57.77 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to advancements in zoonotic disease diagnostics and therapeutics, rising adoption of one health approaches, increasing government funding for zoonotic disease control, growing vaccination coverage in animals, expansion of global disease surveillance programs. Major trends in the forecast period include rising incidence of zoonotic disease outbreaks, increasing focus on preventive treatment and prophylaxis, growing demand for broad-spectrum anti-infective therapies, expansion of integrated animal and human health programs, emphasis on early diagnosis and rapid treatment initiation.

Global Zoonotic Disease Treatment Market Segmentation

1) By Disease Type: Rabies, Tuberculosis, Leishmaniasis, Ebola Virus Disease, Other Disease Types 2) By Drug Class: Anti-Fungal, Anti-Bacterial, Antibiotics, Other Drug Classes 3) By Causative Agent: Bacteria, Virus, Nematode, Rodents, Ticks, Other Causative Agents 4) By Route Of Administration: Oral, Topical, Other Routes Of Administrations 5) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels Subsegments: 1) By Rabies: Post Exposure Prophylaxis (PEP), Pre-Exposure Prophylaxis (PrEP) 2) By Tuberculosis: Latent Tuberculosis Treatment, Active Tuberculosis Treatment 3) By Leishmaniasis: Visceral Leishmaniasis, Cutaneous Leishmaniasis, Mucocutaneous Leishmaniasis 4) By Ebola Virus Disease: Pre-Exposure Vaccination, Post-Exposure Treatment 5) By Other Disease Types: Zika Virus, Lassa Fever, Yellow Fever, Chikungunya

What Are The Drivers Of The Zoonotic Disease Treatment Market?

The increased demand for animal proteins is expected to propel the growth of the zoonotic disease treatment market going forward. Animal proteins are proteins derived from animal sources, such as meat, dairy, eggs, and fish, and contain all essential amino acids necessary for human health. The increased demand for animal proteins is due to the rising global population, higher income levels, urbanization, and growing awareness of the nutritional benefits of animal-based foods. Zoonotic disease treatments offer insights for managing diseases stemming from animal proteins, understanding transmission routes, developing effective therapies, and implementing preventive measures to mitigate public health risks. For instance, in March 2025, according to the Australian Bureau of Statistics (ABS) is an Australia-based official national statistical agency, meat and poultry products per capita increased by 2.3% compared with 2023-24. This reflects a clear rise in animal-based protein intake by weight in the national diet. Therefore, the increased demand for animal proteins is driving the growth of the zoonotic disease treatment industry. Growing global livestock production is expected to propel the growth of the zoonotic disease treatment market going forward. Livestock production refers to the systematic, human-managed breeding, raising, keeping, and utilization of domesticated animals (livestock) to generate food, fiber, labor, and other products for human consumption or use. Growing global livestock production is increasing due to the rising demand for animal-based food products driven by population growth and changing dietary preferences. Livestock production supports zoonotic disease treatment by serving as a critical interface for surveillance, research, and management of animal health, enabling early detection of pathogens, development of vaccines and therapeutics, and implementation of biosecurity practices that reduce transmission between animals and humans while strengthening integrated One Health responses. For instance, in July 2025, according to the official statistics, a UK-based government agencies, in 2024, the total value of livestock output in the UK was £20.1 ($23.69) billion, up £1.1 ($1.30) billion (+5.6%) compared with 2023. This growth was largely driven by higher prices and increased production in eggs, beef, and milk sectors. Therefore, growing global livestock production is driving the growth of the zoonotic disease treatment industry.

Key Players In The Global Zoonotic Disease Treatment Market

Major companies operating in the zoonotic disease treatment market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis International AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Zoetis Inc., Boehringer Ingelheim International GmbH, Elanco Animal Health Incorporated, IDEXX Laboretories Inc., Hikma Pharmaceuticals PLC., Ceva Santé Animale, Vir Biotechnology Inc., Virbac, Vetoquinol S.A., BioCryst Pharmaceuticals Inc, Heska Corporation

Global Zoonotic Disease Treatment Market Trends and Insights

Major companies operating in the zoonotic disease treatment market are focused on investing in zoonotic disease treatment to enhance diagnostic capabilities and improving treatment protocols. This includes developing advanced diagnostic technologies, such as PCR kits, to facilitate quicker identification of zoonotic pathogens and implementing targeted therapeutic interventions. For instance, in October 2023, BioPerfectus, a China-based biotechnology company specializing in diagnostic solutions, launched the addition of thirteen new members to its Zoonotic Infectious Diseases Total PCR Solution. This enhancement aims to bolster its diagnostic capabilities for zoonotic diseases, which account for over 60% of known infectious diseases and 75% of emerging infections. The initiative is designed to improve health security preparedness and response, particularly as climate change facilitates the spread of infectious diseases to new regions. With these new products, the company aims to enable quicker diagnoses and better management of zoonotic infections, highlighting the importance of proactive public health measures.

Regional Outlook

North America was the largest region in the zoonotic disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Zoonotic Disease Treatment Market?

The zoonotic disease treatment market consists of revenues earned by entities by providing services such as antimicrobial therapy, supportive care, vaccinations, and vector control. The market value includes the value of related goods sold by the service provider or included within the service offering. The zoonotic disease treatment market also includes sales of antimicrobial medications (antiparasitic, immunomodulators), diagnostic kits, and vector control products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.